Galectin Therapeutics stock is a completely technical play on an oversold chart setup. This is a quick swing move up gambit as the company reports Phase 2b top-line data.
Galectin Therapeutics stock looks like a compelling swing long setup on the chart. The gambit is a bounce off its 200 day moving average support.
Continue reading “Galectin Therapeutics Stock Swing Long Chart Setup”
Sorrento Therapeutics stock has a buy signal on the Twiggs Money Flow while the stock consolidates. This is one of my favorite divergence patterns to trade.
Sorrento Therapeutics stock is consolidating while the Twiggs Money Flow has broken positive.
Continue reading “Sorrento Therapeutics Stock Consolidating On a Rising Twiggs Money Flow”
BioMarin Pharmaceutical stock is putting in a basing pattern after a big sell-off. The company has recently put in some impressive growth numbers.
BioMarin Pharmaceutical stock has formed a basing or consolidation pattern on the chart with a good looking double bottom put in.
Continue reading “BioMarin Pharmaceutical Stock Doing Double Bottom Consolidation”
Abbott Laboratories stock is uptrending in a continuation pattern. The company beat on earnings and revenue and has since consolidated.
Abbott Laboratories stock is in a continuation pattern and has given a couple of bullish pocket pivot signals over the last week or so.
Continue reading “Abbott Laboratories Stock Gives Pocket Pivot Signals”
Celgene stock has formed a great looking consolidation or basing pattern after dropping -35% on news that was not too bad. I think we have a great bottom feeder play here.
Celgene stock looks like a good oversold setup. The stock plunged -35% when the news broke that Celgene stopped its phase 3 trial of REVOLVE and lowered guidance for 2020. I think the sell-off that followed is now over.
Continue reading “Celgene Stock Now Oversold After Miss and Stopped REVOLVE Trial”
In this slow growth environment, you want to focus on companies that can deliver the growth and that don’t need the economy to do well.
We track more than 110 stocks currently on GuerillaStockTrading that are part of our watch list. It is a broad and diverse group of stocks that are small cap, mid cap, large cap, and mega cap. We track earnings and revenue reports and all news for these stocks. A pattern has emerged this earnings season that you need to know about.
Continue reading “What Stocks To Buy In This Slow Growth Economy”
Below are the top earnings and/or revenue beats for the week ending November 10, 2017. The table below is sorted by the biggest beats in descending order (at the top).
Continue reading “Top Earnings Beats For the Week Ending November 10 2017”
Strong technical setup with bullish sentiment from analysts. The company is also a strong seasonal play. The company was also recently ranked #11 on Fortune’s 100 Fastest Growing Companies list.
AMN Healthcare Services chart shows a beautiful setup with rising large players volume and a pocket pivot signal.
AMN Healthcare Services is also a good seasonal play. Over the next 10 weeks, AMN Healthcare Services has on average historically risen by 9.4% based on the past 15 years of stock performance. AMN Healthcare Services has risen higher in 12 of those 15 years over the next 10 week period, corresponding to a historical probability of 80%.
Continue reading “AMN Healthcare Services Pocket Pivot and Rising Large Players Volume”
China Cord Blood Corporation had a buy signal on the Twiggs Money Flow on Friday, October 27, 2017. A pocket pivot signal was also triggered in the stock on Friday.
Continue reading “China Cord Blood Corporation Gets Twiggs Money Flow Buy Signal”
Aurinia Pharmaceuticals got a new $11 price target from Canaccord Genuity today. Dang! That’s only 91.3% upside from the current price of $5.75!
The upgrade seems to be about Voclosporin (VCS), Aurinia Pharmaceutical’s investigational therapy for patients with active lupus nephritis and moving through Phase III testing. As VCS is directed to an autoimmune disease that has been targeted by Big Pharma companies looking for the next multi-billion dollar drug (FBR projects VCS could achieve more than $2 billion in annual peak sales), Aurinia could receive an acquisition bid from a Big Pharma company at $11 per share.
Continue reading “Aurinia Pharmaceuticals Gets 91% Upside PT From Canaccord Genuity”